Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.86 -1.17%

-$0.11 today

Market cap
$1.29B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.08M

Average 3.00M

Returns on capital

Ocular Therapeutix, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-40.6%

avg 113.0%

ROIC

-35.5%

avg -63.2%

ROA

-32.9%

avg -56.0%

Analysis

ROA is currently the strongest return metric at -32.9% versus its period average of -56.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Pravin U. Dugel

Executive Chairman, President & Chief Executive OfficerUSD 1.77M62——

Donald Notman Jr.

Chief Operating Officer (Leave of Absence)USD 969.18K———

Nadia K. Waheed

Chief Medical OfficerUSD 935.8K49——

Sanjay Nayak MBBS

Chief Strategy OfficerUSD 845.65K56——

Steve Meyers

Chief Commercial OfficerUSD 808.68K———

Jeffrey S. Heier

Chief Scientific OfficerUSD 676.55K65307.46K0.14%

Jason Robins

CFO & Principal Accounting Officer—49——

William H. Ransone

Vice President of Global Sales & Marketing————

William S. Slattery Jr.

Vice President of Investor Relations————

Peter K. Jarrett

Chief Technical Officer—69——

Todd Anderman

Chief Legal Officer & Corporate Secretary—44140.48K0.06%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$461,354.14

Sells

29

$3.25M

Net Transaction Value

−$2.79M

Net selling

Most Active

Kaiser Peter

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

Saroj Namrata

Direct

Sell$231.7K
Oct 8, 26

Anderman Todd

Direct

Sell$87.4K
Oct 2, 26

Kaiser Peter

Direct

Sell$70.4K
Oct 2, 26

Heier Jeffrey S.

Direct

Sell$76.6K
Aug 31, 26

Notman Donald

Direct

Sell$11.3K
Aug 24, 26

Kaiser Peter

Direct

Sell$32.7K
Aug 24, 26

Nayak Sanjay

Direct

Sell$20.4K
Aug 24, 26

Heier Jeffrey S.

Direct

Sell$35.5K
Aug 24, 26

Dugel Pravin

Direct

Sell$233.2K
Jun 3, 26

Waheed Nadia

Direct

Sell$122.6K

1–10 of 30

Summary

Insiders reported 1 buys worth $461,354.14 and 29 sells worth $3.25M over the last 12 months. That adds up to net selling of $2.79M. Kaiser Peter was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+0.2%
+80.5% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +0.2% over three years. Forward estimates point to Revenue at +80.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Ocular Therapeutix, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about OCUL's management, answered from reported figures.

Who manages OCUL?

Ocular Therapeutix, Inc. (OCUL) lists 11 active executives. The top listed executive is Jason Robins, CFO & Principal Accounting Officer.

Are OCUL insiders buying or selling?

Recent insider activity shows net buying of $88.59M.